Exicure, Inc. (XCUR) - Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. Exicure, Inc. is a smaller reporting company that historically focused on nucleic acid therapies but suspended R&D in 2022 to explore strategic alternatives. In January 2025, the Company pivoted by acquiring GPCR Therapeutics USA Inc. (GPCR USA), a subsidiary focused on a Phase 2 clinical trial for blood cancer (Multiple Myeloma). The Company also formed a new South Korean subsidiary, KC Creation, to explore renewable energy and entertainment content opportunities.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $500,000 |
| Net Income (Loss) | $3.01 million | ($0.83 million) |
| Operating Income (Loss) | $2.95 million | ($0.84 million) |
| Cash and Cash Equivalents | $10.42 million | $1.57 million |
| Total Assets | $20.68 million | $15.06 million |
| Total Liabilities | $9.30 million | $8.28 million |
| Stockholders' Equity | $11.38 million | $6.77 million |
Key Drivers: The reported net income is primarily driven by a non-cash $5.97 million gain on the early termination of the Chicago lease. Operating expenses increased to $3.03 million (including $0.81 million in R&D related to the new GPCR USA acquisition) compared to $1.34 million in the prior year.
Material Changes vs. Prior Period
- Acquisition of GPCR USA: On January 19, 2025, Exicure acquired GPCR USA for a total consideration of approximately $7.88 million (cash, equity, and contingent consideration). This introduced $3.34 million in Goodwill and $3.78 million in Intangible Assets (IPR&D) to the balance sheet.
- Lease Termination: The Company terminated its Chicago lease effective January 31, 2025, recognizing a $5.97 million gain. This reversed a significant liability and eliminated future rent obligations.
- Capital Raising: The Company raised approximately $1.6 million in Q1 2025 through common stock offerings (Shin Chang Partners and RMS0718). This follows significant equity raises in late 2024 (HiTron, SangSang, MIRTO).
- Revenue Decline: Revenue dropped to zero from $500,000 in Q1 2024, as the prior year included a one-time license payment that did not recur.
Outlook, Risks, and Contingencies
- Going Concern: Management has expressed substantial doubt about the Company's ability to continue as a going concern for the next 12 months. Current cash ($10.4 million) is deemed insufficient to fund operations and the GPCR USA clinical trial without additional financing.
- Contingent Consideration: The GPCR USA acquisition includes a contingent consideration liability of $5.38 million, payable based on future clinical and commercial milestones. This liability is remeasured quarterly.
- Nasdaq Compliance: The Company recently regained compliance with Nasdaq listing requirements (specifically the $2.5 million stockholders' equity rule) as of December 2024 but remains under a one-year monitoring period. Failure to maintain compliance could result in delisting.
- Legal Proceedings: A securities class action settlement of $5.625 million was approved in January 2025. While covered by insurance, the Company has accrued approximately $1.1 million for its self-insured retainer. Derivative lawsuits and an employee separation lawsuit remain in discovery or settlement discussions.
- Internal Controls: Management identified a material weakness in internal controls over financial reporting related to the review of non-routine activities and lack of IT controls.
Investor Verification Checklist
- Cash Burn Rate: Verify the specific monthly cash burn rate required to fund the GPCR USA Phase 2 trial and determine if the $10.4 million cash balance is sufficient for the next 12 months.
- Financing Plans: Confirm the status of any planned equity offerings or strategic partnerships required to alleviate the "substantial doubt" regarding going concern status.
- Contingent Liability Valuation: Review the assumptions (probability of success, discount rates) used to value the $5.38 million contingent consideration, as changes could significantly impact future earnings.
- Nasdaq Status: Monitor the Company's ability to maintain the $2.5 million equity requirement throughout the mandatory one-year monitoring period.
- Legal Accruals: Track the status of the $1.1 million self-insured retainer accrual and any potential additional costs from the derivative or employee lawsuits.